I strongly disagree with your three year dead money prediction. Those who actually follow the Sunrise trial know that a new site has been added every day for last three months. More than 120 sites are operating in the US and in many countries around the world.
As anyone who closely follows the Sunrise trial knows, there are early look-ins in the trial protocol allowing a Data Monitoring Committee to review the results well before the scheduled trial completion.
Based on the laboriously reconstructed Phase II Trial data, which did persuade the FDA to grant approval to the Phase III trial, some of us expect the data the DMC sees will be so good that the trial will be halted and Peregrine will go to the FDA for approval.
Those of us who follow Peregrine closely know that Bavi was given fast track status by the FDA for a reason. There is a compelling need for new treatment for second line NSCLC patients. As you may recall the much maligned Phase II trial showed solid evidence of increased survival time with no toxicity due to Bavi.
If the trial does not succeed, you may be right about dead money. If the trial does succeed as many of us expect, money invested in our shares will be alive and very well indeed.
GLTA, Paul